NCT03544905 2025-04-22
Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33
Haihe Biopharma Co., Ltd.
Phase 1 Completed
Clinical Trials
9 trialsNCT01976741 2021-05-06
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Bayer
Phase 1 Completed
NCT01149720 2019-02-12
Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Completed
NCT01173913 2019-01-10
Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir
The Netherlands Cancer Institute
Phase 1 Completed
NCT02536391 2016-11-02
Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects
Genentech, Inc.
Phase 1 Completed
NCT00941863 2016-03-22
Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)
Bayer
Phase 1 Completed
NCT02563951 2016-01-08
Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers
Maxinase Life Sciences Ltd.
Phase 1 Completed
NCT00667485 2014-01-17
Rapamycin Plus Bevacizumab in Advanced Cancers
University of Chicago
Phase 1 Completed
NCT01697020 2013-12-02
Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions
Nova Laboratories Limited
Phase 1 Completed